GAPDH ELISA kit (Human)

SKU: SEB932Hu

Size: 96Tests

# of Times Cited in literature: 5

Prepare Time: 1-3 days(please inquire for mutiple units)

Target Name: GAPDH

Target Full Name: Glyceraldehyde-3-Phosphate Dehydrogenase

Alternative Names: G3PD; GAPD; Peptidyl-cysteine S-nitrosylase GAPDH

Target Species: Human

Uniprot: P04406

Gene ID: 2597

Featured Series: SE kit

Featured Series Function: Detects protein (regular version)

Specificity: Reactive with Human GAPDH / Glyceraldehyde-3-Phosphate Dehydrogenase

Method: Colormetric

Detection principle: Double-antibody Sandwich

Detection range: 1.56-100ng/mL

Sensitivity: 0.56ng/mL

Assay Time: 3h

Sample Size: 100uL

Recommended/Predicted Sample Types: Tissue Homogenates, Cell Lysates, Cell Culture Supernates and other Biological Fluids

Assay Precision: Intra-Assay: CV<10%, Inter-Assay: CV<12%

Reproducibility test menthod: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100

Storage: 4°C for 1 month/ -20°C for long-term(One year within shelf life)

Shelf-life: 12 months

Specificity: This assay has high sensitivity and excellent specificity for detection of Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH). No significant cross-reactivity or interference between Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) and analogues was observed.

Stability: The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Assay procedure summary: 1. Prepare all reagents, samples and standards; 2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C; 3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C; 4. Aspirate and wash 3 times; 5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C; 6. Aspirate and wash 5 times; 7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C; 8. Add 50µL Stop Solution. Read at 450nm immediately.

Test principle: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Research Area: Enzyme & Kinase;Metabolic pathway;Cardiovascular biology;Hepatology;Nutrition metabolism;

References Citing This Product: Inactivation of the p53–KLF4–CEBPA Axis in Acute Myeloid Leukemia

Inactivation of the p53–KLF10–CEBPA Axis in Acute Myeloid Leukemia

Untangling the response of bone tumor cells and bone forming cells to matrix stiffness and adhesion ligand density by means of hydrogels

Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid Leukemia

BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. Cancers 2021, 13, 581